Neumora Therapeutics Inc NMRA-511 Update Conference Call Transcript
Ladies and gentlemen, thank you for standing by. (Operator Instructions) Please be advised that today's event is being recorded. I would now like to turn the call over to Helen Rubenstein, Vice President, Investor Relations and Communications at Neumora. Please go ahead.
Good morning, everyone, and thank you for joining us today to discuss top-line data from the Phase Ib signal-seeking study with NMRA-511 in Alzheimer's disease agitation. Before we begin, I'd like to point out that this presentation contains forward-looking statements, which are based on our current expectations and beliefs. We have a number of important disclosures on this slide, which we urge you to read. With me today are several members of Neumora's management team, including Co-Founder, Chief Executive Officer and Chairman, Paul Burns; President, Josh Pinto; Chief Scientific Officer, Nick Brandon; and Chief Operating and Development Officer, Bill Aurora. With that, I'll now turn the call over to Paul to begin. Paul?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
